Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
12.33
-0.17 (-1.36%)
At close: Feb 19, 2026, 4:00 PM EST
12.43
+0.10 (0.81%)
After-hours: Feb 19, 2026, 4:10 PM EST
Tenax Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
504.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Apr 30, 2015 | 49.29K | -109.64K | -68.99% |
| Apr 30, 2014 | 158.93K | -1.03M | -86.66% |
| Apr 30, 2013 | 1.19M | 827.15K | 227.37% |
| Apr 30, 2012 | 363.78K | 260.61K | 252.61% |
| Apr 30, 2011 | 103.17K | 47.43K | 85.09% |
| Apr 30, 2010 | 55.74K | - | - |
| Apr 30, 2009 | - | - | - |
| Apr 30, 2008 | - | - | - |
| Apr 30, 2007 | - | - | - |
| Apr 30, 2006 | - | - | - |
| Apr 30, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 246.72M |
| Ginkgo Bioworks Holdings | 180.61M |
| Zevra Therapeutics | 84.39M |
| ADC Therapeutics | 75.21M |
| Gossamer Bio | 44.05M |
| Prothena Corporation | 11.79M |
| Ocugen | 5.37M |
| Lyell Immunopharma | 41.00K |
TENX News
- 15 days ago - Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewsWire
- 5 weeks ago - Tenax Therapeutics: A Speculative Buy - Seeking Alpha
- 6 weeks ago - Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
- 2 months ago - Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - GlobeNewsWire
- 3 months ago - Tenax Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript - Seeking Alpha
- 3 months ago - Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF - GlobeNewsWire